Endo Pharmaceuticals Holdings (ENDP)

Q3 2011 Earnings Call

October 27, 2011 10:00 am ET


Alan G. Levin - Chief Financial Officer and Executive Vice President

Julie H. McHugh - Chief Operating Officer

Ivan P. Gergel - Executive Vice President of Research & Development

Blaine T. Davis - Vice President of Investor Relations & Corporate Communications

David P. Holveck - Chief Executive Officer, President, Director, Chief Executive Officer of Endo Pharmaceuticals Inc and President of Endo Pharmaceuticals Inc


Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Annabel Samimy - Stifel, Nicolaus & Co., Inc., Research Division

Gary Nachman - Susquehanna Financial Group, LLLP, Research Division

David Amsellem - Piper Jaffray Companies, Research Division

Marc Goodman - UBS Investment Bank, Research Division

Michael Faerm - Crédit Suisse AG, Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Corey B. Davis - Jefferies & Company, Inc., Research Division

John T. Boris - Citigroup Inc, Research Division



Good day, ladies and gentlemen, and welcome to the Quarter Three 2011 Endo Pharmaceuticals Earnings Conference Call. My name is Laura, and I will be your operator for today. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. And now I'd like to turn the call over to Mr. Blaine Davis, Vice President of Corporate Affairs. Please proceed, sir.

Blaine T. Davis

Thanks, Laura. Good morning, everyone, and thank you for joining us. With me on today's call are Dave Holveck, President and CEO of Endo; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Executive Vice President of R&D; Alan Levin, Executive Vice President and Chief Financial Officer; as well as Tony Bihl, Group President of American Medical Systems. After our prepared remarks, we'll open the call and take your questions.

I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and subject to change, risks and uncertainties described in today's press release and in our filings with the SEC.

In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review Endo's current report on Form 8-K filed with the SEC for Endo's reasons for including those non-GAAP financial measures in this earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our sales and earnings press release issued earlier this morning.

With that, I'd like to turn the call over to Dave.

David P. Holveck

Thank you, and good morning. Endo had a strong third quarter, with record revenues of $759 million and adjusted diluted earnings per share of $1.25. These results reflect our continued focus on integration of our newly acquired businesses, solid demand for our products and our commitment to financial discipline and debt reduction.

Our core business has continued to grow and performed well, with strong contributions from OPANA ER, Voltaren Gel and LIDODERM. Sales of branded and non-promoted drugs in our legacy business rose 17% year-over-year. Our acquisitions have added growth and created substantial diversification for our company.

In the third quarter, the Generics and Devices and Services segments contributed 44% of company revenues. You may recall that we significantly increased our financial guidance during our August earning call. Reflecting on our continued focus on robust operational execution this year, we are reaffirming that guidance for 2011 of $2.72 billion to $2.8 billion in revenue and adjusted diluted earnings per share of $4.55 to $4.65.

But consistent with our strategic objectives, the primary use of our free cash is to pay down debt. During the quarter, we made payments of $151 million to reduce term loan debt associated with our recent acquisition of American Medical Systems. Over the last several months, we solidified our expectations for the range of revenue and costs synergies associated with the AMS transaction.

We've taken steps to solidify our relationships with urologists and urogynecologists. Those relationships are an important driver of growth in our urology franchise. We are now calling on a majority of urologists in the United States, up significantly from last year. Importantly, there is relatively minimal overlap across the different components of our commercial organization. This, we believe, will ultimately lead to a larger number of more comprehensive relationships with providers and a higher return on our promotional investments.

We've identified potential cross-selling opportunities for the AMS Men's Health franchise and FORTESTA Gel. In addition, the company is exploring opportunities to expand the utilization of Endocare cryoablation therapy and the AMS GreenLight laser through our HealthTronics franchise. These and other initiatives are now being piloted by our commercial organization, and we expect to see the results of this pilot effort early next year, at which time, we will assess whether these efforts should be scaled nationally.

Looking forward, we believe that having good data is critical to enhancing the organic growth potential of our urology franchise. Data gives us unique insights into our customers, both providers and payers, and helps us chart the path forward in urology.

In order to support this strategy, our HealthTronics business recently made 2 strategic investments in UroChart and meridian, 2 profitable providers of electronic medical records software for urologists. These investments will enhance HealthTronics service offerings in the urology practice management and further solidify Endo's contractual relationship with approximately 1,800 practicing urologists, many of whom are new to Endo.

Read the rest of this transcript for free on seekingalpha.com

If you liked this article you might like

Study: Over-the-Counter Meds More Effective For Chronic Back Pain Than Opioids

Study: Over-the-Counter Meds More Effective For Chronic Back Pain Than Opioids

Attorney General Sessions Announces New Federal Opioids Taskforce

Attorney General Sessions Announces New Federal Opioids Taskforce

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

NYC Joins Cities, Counties and States In Bringing Opioid Lawsuit

NYC Joins Cities, Counties and States In Bringing Opioid Lawsuit

Why Hospitals Shouldn't Terrify Generic Drug Companies

Why Hospitals Shouldn't Terrify Generic Drug Companies